• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
160628 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
* J, E1 x* C: C  Q9 @$ Y8 Q4 \* m: |3 h
& w# y1 u4 j- r) j
Sub-category:2 x8 U8 l# ?$ l& b3 {9 U
Molecular Targets
8 Q9 x5 P& K; o: W  {# {' b( c+ H$ e; `6 _, `! o" o
3 s( N. B2 h9 ^! w; Y
Category:% n# n; H! C; m5 y7 j! q& D1 F
Tumor Biology
  h' H8 v5 Y0 A) a& R! `
( ~; w% }1 [1 j! M; w: _- R. v
% d8 s. E( j8 {8 J; U. L- KMeeting:
3 X% {5 G8 E: o/ U: A2011 ASCO Annual Meeting & ?- m2 D6 F6 Z0 l/ Z2 ?( a* Q9 [
, K1 B! q6 x$ \" X5 J! H; [
4 W8 g5 I- {8 I8 }* ]8 Y+ A& j9 a
Session Type and Session Title:/ i9 N: V& Q9 L( p' }
Poster Discussion Session, Tumor Biology ( M$ @& H) t4 `9 M
: Z& |5 _& N3 R, ^

( x2 o- ^3 ]8 l$ fAbstract No:
* \4 v4 M9 W: t" q10517 - e% N& Q  y) W

* h1 x) O8 i0 ?( }4 m( f& S2 @! e( k) C: A
Citation:
! k3 x8 ~3 ~1 u( _# v. SJ Clin Oncol 29: 2011 (suppl; abstr 10517) 6 U/ f1 K5 K8 q, c- _  [

$ V0 S3 X( y  k9 p
& H- K$ i- J' B8 C  EAuthor(s):" k0 ?5 M3 @6 A8 B% C# h4 K
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " U& z1 l8 u5 H/ x

" x9 y8 D+ I: U! U
& S  |5 B9 H3 c2 z* d% i
& q9 A, z" p* L: XAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.' Y/ k' R6 {4 ?% ~

( w2 H' F: O; N1 ]& h0 M8 a6 {Abstract Disclosures" M( @; a5 F3 O7 N$ ~7 r: d; G

, @1 c* E! v- p  t- OAbstract:5 ?6 G# K8 G7 y* z- \

0 U1 ~+ J/ a( S7 k1 I2 ^9 Z3 w0 Q& \5 C' u
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.4 o9 {( S3 _# Y6 E* o
; f8 c7 o! ~3 W7 K1 A

8 x! {4 \6 G; Y% h; c! @
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
  v8 u% N* B" U3 F没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
9 {8 @! C5 m. j& S9 n/ j, u, A( P0 R
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
1 f* T. s+ D; c- u易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
- F% j# ?2 ~' LALK一个指标医院要900多 ...
, P2 r, D, z- y' A$ l' S; Y' M! v
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
4 z$ f$ S# f/ k
( L2 d$ N& ^% Y8 |2 l  m" i现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表